Background: Soluble ST2 (sST2) receptor is secreted and detectable in human serum, which acts as a decoy receptor for interleukin (IL)-33 to prevent IL-33-mediated Th2 immune responses. Recently, elevated serum sST2 has been found to be a novel biomarker in cardiovascular diseases such as heart failure and atherosclerosis. Here, we studied the role of sST2 in acute ischemic stroke (AIS) and its relationship with several inflammatory markers. Methods: The study included 112 patients with first-ever acute ischemic stroke, who were admitted within 48 hours after stroke onset. The serum levels of sST2 and IL-33 were measured with ELISA and the severity of AIS patients was evaluated based on the National Institutes of Health Stroke Scale (NIHSS) score. The cerebral infarct volume was calculated according to the Pullicino formula based on the cranial CT scan or MRI. High-sensitivity C-reactive protein (hs-CRP) and serum amyloid A protein (SAA) were measured using the latex-enhanced immunoturbidimetric assay. Results: The serum sST2 level was significantly increased in patients with AIS compared to the control patients without AIS. In addition, the concentration of serum sST2 increased with the infarct volume and the severity of AIS evaluated based on the NIHSS score. Furthermore, the sST2 level correlated positively with the inflammatory marker hs-CRP. Conclusions: Our study suggests that sST2 may be used as a novel diagnostic and predicting inflammatory marker in AIS. (Clin. Lab. 2018;64:xx-xx.
INTRODUCTION
ST2 is a member of the Toll-like/IL-1-receptor superfamily, which was characterized over a decade before interleukin (IL)-33 was discovered to be its specific ligand [1, 2] . ST2 exists in two isoforms, a full-length transmembrane form (ST2L) and a secreted soluble form (sST2) [3] . IL-33 is a multifunctional immunomodulatory cytokine, which may induce Th2 immune responses in the different disease states or experimental conditions via the receptor complex consisting of ST2L and IL-1 receptor accessory protein [3, 4] . Conversely, sST2 acts as a decoy receptor by binding IL-33 to prevent its signaling through ST2L [5] . The IL-33/ST2 signaling pathway has been implicated in numerous inflammatory diseases [6, 7] . As the key molecule in this axis, elevated serum sST2 has been reported as a valuable inflammatory biomarker in several Th2-related diseases such as asthma and sepsis, and its high-level has also been observed in several cardiovascular diseases such as atherosclerosis and heart failure [8] [9] [10] [11] . Acute ischemic stroke (AIS) is a leading cause of morbidity, mortality, and disability worldwide, which causes cerebral ischemia with activation of an inflammatory response leading to the exacerbation of primary brain injury. Our previous study has found that IL-33 may ameliorate ischemic brain injury in experimental stroke through promoting Th2 response [12] . Several recent studies have also suggested the role of IL-33/ST2 axis in acute cerebral infarction [13, 14] . In fact, reports relating sST2 to the central nervous system (CNS) are still sparse. Experimental studies have suggested that sST2 is highly expressed in astrocytes and microglia, and these two cells may participate in the inflammatory response after stroke [15] . Recently, the high level of serum sST2 has been found to be associated with incident stroke/transient ischemic attack (TIA) [16] . The elevated sST2 has also been shown to be related to worse outcome and higher mortality after AIS [17] . However, the conclusions from another study in a large cohort of AIS patients revealed that serum sST2 may not be a strong and independent prognostic marker for AIS mortality [18] . To date, the relationship between circulating levels of sST2, stroke severity, and post-ischemic inflammation has not been well elucidated. The aim of this study was to examine the level of serum sST2 in relation to disease severity and clinical association in patients with AIS, and its relationship with the inflammatory biomarkers high-sensitivity C-reactive protein (hs-CRP) and serum amyloid A protein (SAA) and then evaluate whether sST2 may be a candidate inflammatory marker in AIS.
MATERIALS AND METHODS

Clinical subjects
The 112 hospitalized patients with AIS were recruited from January to May 2017 in the Department of Neurology of Zhongnan Hospital of Wuhan University. The inclusion criteria were clinical presentation of first-ever stroke, age 18 years or older, and diagnosed as having acute cerebral infarction using CT or MRI scan within 48 hours. The exclusion criteria were no serum samples collected, uncertain diagnosis or symptom onset of AIS, and receiving thrombolysis therapy. The control group was selected from 78 patients who were evaluated with physical examination, laboratory tests and imaging studies, and diagnosed without AIS. Patients were excluded with the following conditions: cerebral hemorrhage, subdural hematoma, intracranial space-occupying lesions, cerebrovascular damage caused by trauma, heart failure, malignant diseases, immunologic diseases, severe infection or pregnancy. The study was approved by the Medicine Research Ethics Committee of Zhongnan Hospital of Wuhan University. All stroke and control patients gave informed consent before enrollment in the study.
Clinical evaluation
A general medical history was collected, including age, gender, risk factors, common complications, and standard laboratory tests. Physical and neurological examinations and cerebral CT or MRI were also performed in all stroke and control patients. AIS subtypes were classified into 5 categories based on etiology, using the TOAST classification: (1) large-artery atherosclerosis (LAA), (2) small vessel occlusion (SVO), (3) cardioembolism (CE), (4) stroke of undetermined etiology (UDE), and (5) stroke of other determined etiology [19] . The cerebral infarct volume was calculated by the Pullicino formula (length x width x layer number/2) based on the cranial CT (49/89 cases) or MRI (40/89) scan within 48 hours after AIS [20] . The patients were accordingly divided into the great infarction group (infarct volume > 10 cm 3 ), middle infarction group (infarct volume 5 -10 cm 3 ), and small infarction group (infarct volume < 5 cm 3 ). The severity of AIS patients was determined on admission using the National Institutes of Health Stroke Scale (NIHSS) score [21] .
Blood collection and laboratory test
Blood samples were collected from each of the 112 fasting patients with AIS within 48 hours of symptom onsets as well as from the 78 fasting control subjects. After standing for 30 minutes, the blood samples were centrifuged for 10 minutes at 3,800 rpm. The sera were separated and allocated to tubes (Eppendorf, Hamburg, Germany) and preserved at -80°C for further analysis. Serum levels of human sST2 and IL-33 were measured according to the enzyme-linked immunosorbent assay (ELISA) kits (Westang Biotech Co, Shanghai, China). Briefly, serum samples were diluted and added to an ELISA plate pre-coated with capture antibody, then followed by biotinylated detection antibody and horseradish peroxidase (HRP)-conjugated secondary mAb, and subsequently developed by adding the enzymatic substrate. The recombinant human sST2 or IL-33 standards diluted to a standard gradient to make a standard curve. Optical density (OD) value (450 nm) was measured using a microplate reader (Multiskan FC; Thermo Scientific, Waltham, MA). Serum levels of IL-33 and sST2 were read off from a standard curve according to the manufacturer's instructions. The basic analytical performances of human sST2 and IL-33 assays were shown in Table 1 . High-sensitivity C-reactive protein (hs-CRP) and serum amyloid A protein (SAA), the common inflammatory parameters in clinic, were also tested on an Olympus 5400 analyzer (Beckman Coulter). Hs-CRP (Sekisui Medical Co., Tokyo, Japan) and SAA (Purebio Biotech Co., Ningbo, China) were both measured using the latex-enhanced immunoturbidimetric assay. The assays were performed at the Medicine Biochemistry Laboratory of Zhongnan Hospital.
Statistical analysis
Data were represented as mean ± standard deviation in normally distributed variables or medians (IQR) in nonnormally distributed variables. The Mann-Whitney Utest and analysis of variance (ANOVA), where appropriate, were used to compare continuous variables between groups. Spearman's correlation was used for correlation analysis. A two-sided p-value of < 0.05 was considered statistically significant. All statistical analyses were performed by IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Clinical characteristics of AIS patients
The baseline characteristics of 112 patients with AIS are shown in Table 2 . The study comprised 62 (55.4%) men and 50 (44.6%) women with a median age of 67 years and median baseline NIHSS of 4 (IQR, 2 -7). The infarct volume measured in the 89 patients with a radiologically confirmed infarction ranged from 0.5 to 20 cm 3 . The gender and mean age distribution did not differ significantly between the AIS and control groups.
Serum levels of sST2 and IL-33 in AIS patients
We first tested the serum levels of sST2 and IL-33 in AIS patients, and our results showed that serum levels of sST2 (0.103 vs. 0.027 ng/mL), as well as the inflammatory parameters hs-CRP (19.87 vs. 1.95 mg/L) and SAA (25.99 vs. 5.67 mg/L) were upregulated after AIS compared to the control subjects (Table 2 ). According to previous reports, serum sST2 might be involved in the inflammatory responses in acute cerebral infarction patients [13] . Nevertheless, there was no significant difference in the serum IL-33 level (29.8 vs. 26.7 pg/mL) between the two groups ( Table 2 ).
Serum level of sST2 and cerebral infarct volume
MRI or CT scans were available for 89 AIS patients. We found that the large infarct volume patient group had the highest serum sST2 levels, which was significantly higher than the medium and small infarct volume groups (p < 0.05) ( Figure 1A ). Linear regression analysis showed that there is a positive relationship between infarct volume and serum sST2 concentration ( Figure  1B ).
Serum level of sST2 and the severity of AIS
According to the NIHSS score, the 112 AIS patients were divided into mild AIS group (NIHSS score < 6, n = 73) and severe AIS group (NIHSS score ≥ 6, n = 39). We found that the level of serum sST2 was significantly higher in the severe AIS group than the mild AIS group. Compared to the control group, the serum sST2 level in the mild AIS group was higher (Table 3) . 
Serum level of sST2 and other inflammatory parameters
We also analyzed the relationship of serum sST2 to some inflammatory parameters such as hs-CRP and SAA. The American Heart Association and U.S. Centers for Disease Control and Prevention have defined hs-CRP risk groups as follows: low risk (hs-CRP < 1.0 mg/L), average risk (hs-CRP 1.0 -3.0 mg/L), and high risk (hs-CRP > 3.0 mg/L) [22] . According to the definition, we divided the AIS patients into low hs-CRP group, average hs-CRP group, and high hs-CRP group, and then tested the serum sST2 level in the different hs- CRP risk groups. The result showed that the level of serum sST2 was significantly higher in the high hs-CRP group than in the low hs-CRP group and average hs-CRP group (Table 4) , and the serum level of sST2 was found to correlate mildly with hs-CRP level ( Figure  2A ). However, serum sST2 level was not found to correlate with the serum level of SAA in AIS patients (Figure 2B) .
DISCUSSION
The present study investigated the change of serum sST2 levels in AIS patients within 48 hours after onset. The results showed that serum sST2 levels were significantly upregulated in AIS patients, and its level increased along with the increased infarct volume and NIHSS score. This finding suggests that the serum sST2 level at the acute phase of AIS may be considered as a novel marker for diagnosis and prognosis in stroke. Recently, there has been an increasing focus on the role of IL-33/ST2 signal pathway in the inflammation of CNS diseases [23, 24] . We have demonstrated the novel role of IL-33 in the modulation of Th1/Th2 balance and Th17 response after cerebral ischemia in the previous study [12] . Then some other studies have also revealed IL-33 may be a protective and anti-inflammatory factor in stroke [13, 14, 21] . As a decoy receptor for IL-33, sST2 can inactivate the function of IL-33 [5] . The increased serum level of sST2 in AIS patients may inhibit the IL-33-driven Th2-type inflammatory response and act as a pro-inflammatory factor, which was in line with the previous study showing it in human serum after stroke and acute myocardial infarction [10, 13] . We also found that the level of sST2 was higher along with the increased infarct volume and NIHSS score. Previous studies have already shown that high inflammatory parameters are associated with the clinical severity and outcome of stroke [25] . Thus, we speculate that serum sST2 may be a novel inflammatory marker for AIS. Here, serum IL-33 levels were not been found to differ between the stroke and control group, suggesting that Th2 immune responses may not be activated effectively in the early stage of AIS. In clinic, hs-CRP has been used to predict patient outcomes in cardiovascular disease and could reflect the inflammatory response after stroke [26, 27] . We found that hs-CRP was significantly higher in AIS patients, and there was a positive correlation between serum sST2 and hs-CRP. SAA is also a sensitive marker of the acute inflammation and its serum concentrations increase in response to infection, trauma or stress. Whether SAA could be used as a specific diagnostic tool in AIS is still inconclusive [28, 29] . Our study showed that the level of SAA was increased after stroke but did not show a significant relationship between SAA and serum sST2.
Taken together, the data suggest that the increased serum sST2 may be more sensitive in response to the acute inflammation than SAA after stroke, and hs-CRP and serum sST2 contribute to the inflammatory response as inflammatory biomarkers in AIS patients. Moreover, there are some limitations in this study, and additional larger sample sizes of AIS patients from multiple centers are needed to validate our findings.
CONCLUSION
In summary, we identified the circulating sST2 levels to be increased in acute ischemic stroke and to be associated with disease severity and clinic association. Its serum concentration also correlated with the changes of hs-CRP, which revealed that sST2 may be a useful marker for diagnosis and prediction of ischemic tissue volume in the progress of acute ischemic stroke.
